Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab

Autor: Ellis LA, Malangone-Monaco E, Varker H, Stetsovsky D, Kubacki M, DeHoratius RJ, Kafka S

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 99-110 (2019)

Lorie A Ellis,1 Elisabetta Malangone-Monaco,2 Helen Varker,3 Diana Stetsovsky,3 Maureen Kubacki,1 Raphael J DeHoratius,1,4 Shelly Kafka1 1Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA; 2Life Sciences, IBM Watson Hea

Externí odkaz: https://doaj.org/article/5b7289f9033d4b4189b710f369c3f10d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

Autor: Kiss S; Weill Cornell Medical College, New York, New York., Malangone-Monaco E; IBM Watson Health, Cambridge, Massachusetts., Wilson K; IBM Watson Health, Cambridge, Massachusetts., Varker H; IBM Watson Health, Cambridge, Massachusetts., Stetsovsky D; IBM Watson Health, Cambridge, Massachusetts., Smith D; IBM Watson Health, Cambridge, Massachusetts., Garmo V; Genentech, South San Francisco, California.

Publikováno v: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2020 Mar; Vol. 26 (3), pp. 253-266. Date of Electronic Publication: 2020 Feb 05.